A nationwide recall has been issued for certain bottles of MAR-Amlodipine 5-milligram tablets after a manufacturing error raised concerns that some packages may contain the wrong medication.
In an advisory released on Feb. 9, Health Canada announced a Type 1 recall affecting two specific lots of the blood pressure drug, which is commonly prescribed to treat hypertension. The recall was initiated after it was discovered that some bottles may have been mistakenly filled with midodrine, a medication used to treat low blood pressure.
A Type 1 recall is the most serious classification, indicating a reasonable probability that use of the affected product could result in severe health consequences or even death.
According to Health Canada, the correct MAR-Amlodipine tablets are white to off-white, eight-sided pills marked with the numbers “210” and “5.” In contrast, midodrine 2.5-milligram tablets are white, round, and bear the inscription “M2” on one side with a score line on the other.
Health officials are urging patients to carefully inspect their medication. Individuals being treated for high blood pressure who accidentally take midodrine could face dangerous side effects, including sharply elevated blood pressure, dizziness, fainting, slowed heart rate, and in severe cases, organ damage.
Patients who notice unfamiliar tablets in their prescription bottles or are uncertain about their medication are advised to return the product to their pharmacy. If a replacement is not immediately available, Health Canada recommends continuing prescribed treatment but avoiding any round tablets found in the bottle.
Authorities also stress the importance of seeking immediate medical care if symptoms such as chest pain, sudden headache, difficulty speaking, weakness, loss of sensation, or fainting occur. Anyone experiencing severe dizziness, abnormal blood pressure readings, or a slow heartbeat should contact a healthcare provider or call emergency services.
Health Canada confirmed that it is overseeing the company’s recall process and investigation. The agency is working with the manufacturer to ensure corrective measures are implemented to prevent similar incidents in the future. Officials added that the public will be informed if additional health risks emerge.
Consumers and healthcare professionals are encouraged to report any adverse reactions or concerns related to health products directly to Health Canada.
